US › Healthcare

Quoin Pharmaceuticals Ltd DRC (QNRX)

US · Healthcare · Biotechnology

$7.01+1.59%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.5M

EPS

$-1.90

EPS estimate

$-1.83

EPS came in at -1.90 against a street estimate of -1.83 — a miss of 3.8%.

Key statistics

Market cap

$13.9M

Forward P/E

0.0

P/B

3.47

Book value

$8.76

EPS (TTM)

$-5.67

52-week high

$23.50

52-week low

$3.25

50-day MA

$5.23

200-day MA

$7.58

Beta

1.73

Analyst view

Analysts rate Quoin Pharmaceuticals Ltd DRC a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $22.20.

Shareholding

Insiders

8.77%

Institutions

66.39%

Largest institutional holders

Fund	Stake
Ikarian Capital, LLC	10.53%
Dauntless Investment Group, LLC	9.79%
Millennium Management LLC	5.59%
SummitTX Capital, L.P	4.99%
Woodline Partners LP	3.96%
Aberdeen Group PLC	3.73%
Soleus Capital Management, L.P.	3.62%
AIGH Capital Management, LLC	3.49%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Quoin Pharmaceuticals Ltd DRC — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.